» Articles » PMID: 37758511

Suppression of Endogenous Insulin Secretion by Euglycemic Hyperinsulinemia

Overview
Specialty Endocrinology
Date 2023 Sep 27
PMID 37758511
Authors
Affiliations
Soon will be listed here.
Abstract

Context: The impact of insulin, particularly exogenous hyperinsulinemia, on insulin secretion in humans is debated.

Objective: We assessed the effects of exogenous hyperinsulinemia on insulin secretion and whether the response is altered in insulin resistance associated with obesity.

Methods: Insulin secretion rates (ISRs) during euglycemic hyperinsulinemic clamp studies (52 volunteers) were calculated using a model that employs plasma C-peptide concentrations. One study involved a 2-step insulin clamp and the other study was a single step insulin clamp. For both studies the goal was to achieve plasma glucose concentrations of 95 mg/dL during the clamp irrespective of fasting glucose concentrations. The percent change in ISR from fasting to the end of the insulin clamp interval was the main outcome. Linear regression and analysis of covariance were used to test for the effects of insulin on ISR and to test for group differences.

Results: ISR was greater in obese volunteers (P < .001) under fasting and hyperinsulinemic clamp conditions. The change in plasma glucose from baseline to the end of the insulin clamp interval was highly correlated with the change in ISR (r = 0.61, P < .001). From baseline to the end of the clamp we observed a 27% (SD 20) suppression of ISR. The participants who underwent a 2-step insulin clamp had greater suppression of ISR during the second step than the first step (P < .001). The proportional suppression of ISR during euglycemic hyperinsulinemia was not different between nonobese and obese groups (P = .19).

Conclusion: Hyperinsulinemia suppresses endogenous insulin secretion and the relative change in insulin secretion produced by exogenous insulin did not differ between nonobese and obese people.

Citing Articles

Impact of setting distinct target blood glucose levels on endogenous insulin suppression and pharmacodynamics of insulin preparations.

Liu H, Li T, Chen X, Yu H, Yu Y World J Diabetes. 2025; 16(2):101779.

PMID: 39959272 PMC: 11718471. DOI: 10.4239/wjd.v16.i2.101779.

References
1.
Faber O, Hagen C, Binder C, Markussen J, Naithani V, Blix P . Kinetics of human connecting peptide in normal and diabetic subjects. J Clin Invest. 1978; 62(1):197-203. PMC: 371754. DOI: 10.1172/JCI109106. View

2.
Aspinwall C, Lakey J, Kennedy R . Insulin-stimulated insulin secretion in single pancreatic beta cells. J Biol Chem. 1999; 274(10):6360-5. DOI: 10.1074/jbc.274.10.6360. View

3.
Lopez X, Cypess A, Manning R, OShea S, Kulkarni R, Goldfine A . Exogenous insulin enhances glucose-stimulated insulin response in healthy humans independent of changes in free fatty acids. J Clin Endocrinol Metab. 2011; 96(12):3811-21. PMC: 3232618. DOI: 10.1210/jc.2011-0627. View

4.
Tao Y, Zhu M, Pu J, Zhang P, Wan L, Tang C . Reduction in C-Peptide Levels and Influence on Pharmacokinetics and Pharmacodynamics of Insulin Preparations: How to Conduct a High-Quality Euglycemic Clamp Study. Front Pharmacol. 2021; 12:786613. PMC: 8675232. DOI: 10.3389/fphar.2021.786613. View

5.
Muscelli E, Pereira J, Lazarin M, Silva C, Pareja J, Saad M . Lack of insulin inhibition on insulin secretion in non-diabetic morbidly obese patients. Int J Obes Relat Metab Disord. 2001; 25(6):798-804. DOI: 10.1038/sj.ijo.0801607. View